The reality of using primaquine.
BACKGROUND: Primaquine is currently the only medication used for radical cure of Plasmodium vivax infection. Unfortunately, its use is not without risk. Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency have an increased susceptibility to haemolysis when given primaquine. This poten...
Main Authors: | Burgoine, K, Bancone, G, Nosten, F |
---|---|
Format: | Journal article |
Language: | English |
Published: |
BioMed Central
2010
|
Similar Items
-
Primaquine-induced haemolysis in females heterozygous for G6PD deficiency
by: Chu, C, et al.
Published: (2018) -
G6PD variants and haemolytic sensitivity to primaquine and other drugs
by: Bancone, G, et al.
Published: (2021) -
The impact of using primaquine without prior G6PD testing: a case series describing the obstacles to the medical management of haemolysis
by: Chu, C, et al.
Published: (2019) -
Primaquine pharmacokinetics in lactating women and breastfed infant exposures
by: Gilder, M, et al.
Published: (2018) -
Using G6PD tests to enable the safe treatment of Plasmodium vivax infections with primaquine on the Thailand-Myanmar border: A cost-effectiveness analysis
by: Devine, A, et al.
Published: (2017)